Table 3.
Changes in haemodynamic and metabolic parameters during treatment with dapagliflozin and vildagliptin
| Total (n = 43) | Dapagliflozin (n = 21) | Vildagliptin (n = 22) | P value | ||||
|---|---|---|---|---|---|---|---|
| Baseline | 6 months | Baseline | 6 months | Baseline | 6 months | ||
| Body weight (kg) | 63.64 ± 12.39 | 63.91 ± 12.41 | 64.57 ± 10.94 | 63.30 ± 10.58 | 62.78 ± 13.83 | 64.48 ± 14.17 | |
| Change from baseline | 0.26 (−0.50, 1.02) | −1.27 (−2.01, −0.53)** | 1.72 (0.72, 2.72)** | <.001*** | |||
| BMI (kg/m2) | 25.37 ± 3.14 | 25.49 ± 3.24 | 25.92 ± 2.95 | 25.43 ± 2.97 | 24.84 ± 3.28 | 25.55 ± 3.55 | |
| Change from baseline | 0.12 (−0.19, 0.43) | −0.49 (−0.80, −0.18)** | 0.71 (0.30, 1.12)** | <.001*** | |||
| WC (cm) | 91.44 ± 9.91 | 91.38 ± 8.65 | 90.74 ± 8.36 | 89.63 ± 7.35 | 92.22 ± 11.58 | 93.32 ± 9.73 | |
| Change from baseline | −0.06 (−1.79, 1.67) | −1.11 (−3.03, 0.82) | 1.09 (−1.97, 4.16) | .436 | |||
| SBP (mmHg) | 124.98 ± 18.51 | 119.15 ± 12.75 | 125.65 ± 21.98 | 115.78 ± 11.41 | 124.33 ± 14.98 | 122.36 ± 13.37 | |
| Change from baseline | −5.83 (−11.24, −0.42)* | −9.87 (−18.00, −1.75)** | −1.97 (−9.42, 5.48) | .166 | |||
| DBP (mmHg) | 68.48 ± 9.02 | 65.74 ± 9.79 | 67.76 ± 8.17 | 63.79 ± 6.52 | 69.17 ± 9.90 | 67.59 ± 11.98 | |
| Change from baseline | −2.74 (−5.60, 0.11) | −3.97(−8.26, 0.32) | −1.58 (−5.66, 2.51) | .636 | |||
| HR (beats/min) | 73.93 ± 8.33 | 73.05 ± 10.02 | 74.00 ± 8.51 | 72.77 ± 1.57 | 73.86 ± 8.34 | 73.33 ± 9.67 | |
| Change from baseline | −0.88 (−3.39, 1.63) | −1.23 (−4.63, 2.18) | −0.52 (−4.53, 3.49) | .567 | |||
| FBS (mg/dL) | 148.00 ± 35.78 | 115.80 ± 33.04 | 154.19 ± 42.27 | 116.86 ± 35.22 | 141.50 ± 26.96 | 114.70 ± 31.47 | |
| Change from baseline | −32.20 (−45.30, −19.09)* | −37.33 (−56.60, −18.07)** | −26.80 (−46.00, −7.60)** | .389 | |||
| HbA1c (%) | 8.18 ± 1.25 | 7.45 ± 1.03 | 8.11 ± 1.36 | 7.48 ± .98 | 8.25 ± 1.18 | 7.41 ± 1.10 | |
| Change from baseline | −0.74 (−1.12, −0.35)* | −0.63 (−1.10, −0.16)** | −0.84 (−1.48, −0.21)** | .220 | |||
| Cholesterol (mg/dL) | 153.55 ± 36.60 | 146.79 ± 38.09 | 146.55 ± 33.79 | 142.80 ± 34.55 | 161.33 ± 38.95 | 151.22 ± 42.23 | |
| Change from baseline | −6.76 (−17.47, 3.95) | −3.75 (−16.17, 8.67) | −10.11 (−29.38, 9.16) | .303 | |||
| HDL‐C (mg/dL) | 46.55 ± 14.18 | 44.26 ± 8.73 | 47.47 ± 17.59 | 43.53 ± 1.16 | 45.63 ± 10.10 | 45.00 ± 7.23 | |
| Change from baseline | −2.29 (−6.20, 1.62) | −3.95 (−11.34, 3.45) | −0.63 (−4.01, 2.74) | .908 | |||
| LDL‐C (mg/dL) | 92.26 ± 38.72 | 86.95 ± 31.25 | 82.72 ± 31.54 | 84.35 ± 29.27 | 101.80 ± 43.49 | 89.55 ± 33.67 | |
| Change from baseline | −5.31 (−16.65, 6.03) | 1.63 (−10.35, 13.61) | −12.25 (−32.24, 7.74) | .341 | |||
| Triglyceride (mg/dL) | 163.92 ± 63.55 | 174.16 ± 89.32 | 164.79 ± 68.58 | 163.89 ± 86.50 | 163.05 ± 59.98 | 184.42 ± 93.24 | |
| Change from baseline | 10.24 (−19.41, 39.88) | −0.90 (−43.83, 42.04) | 21.37 (−23.13, 65.36) | .452 | |||
| GFR (mL/min/1.73m2) | 72.43 ± 19.62 | 70.52 ± 20.53 | 74.32 ± 17.48 | 74.66 ± 17.53 | 70.45 ± 21.93 | 66.17 ± 22.92 | |
| Change from baseline | −1.91 (−6.28, 2.45) | 0.34 (−7.34, 8.02) | −4.28 (−8.77, 0.21) | .251 | |||
| Haemoglobin (g/dL) | 12.30 ± 1.71 | 12.73 ± 2.04 | 12.59 ± 1.10 | 13.57 ± 1.51 | 12.01 ± 2.01 | 11.91 ± 2.18 | |
| Change from baseline | 0.43 (0.10, 0.75)* | 0.98 (0.54, 1.42)** | −0.10 (−0.48, 0.29) | .001*** | |||
| Mean platelet volume (fL) | 8.56 ± 0.10 | 8.84 ± 1.25 | 8.98 ± 1.05 | 8.89 ± 1.05 | 8.15 ± 0.74 | 8.79 ± 1.07 | |
| Change from baseline | 0.28 (−0.06, 0.62) | −0.09 (−0.59, 0.40) | 0.64 (0.19, 1.10)** | .011*** | |||
| NT‐proBNP (pg/mL) | 645.19 ± 1406.99 | 314.47 ± 335.06 | 433.94 ± 516.52 | 309.83 ± 314.01 | 837.23 ± 1882.13 | 318.70 ± 360.46 | |
| Change from baseline | −330.72 (−733.34, 71.90) | −124.12 (−284.01, 35.78) | −518.54 (−1296.14, 259.07) | .465 | |||
| hs‐TnT (pg/mL) | 16.15 ± 13.09 | 16.00 ± 14.88 | 14.67 ± 10.31 | 12.18 ± 9.67 | 17.50 ± 15.30 | 19.48 ± 17.91 | |
| Change from baseline | −0.15 (−1.68, 1.38) | −2.49 (−4.50, −0.47)** | 1.98 (−0.02, 3.97) | .002*** | |||
Data are means ± standard deviation or (95% confidence interval of the difference). P < .05 was considered significant. BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; FBS, fasting blood sugar; HbA1c, haemoglobin A1c; GFR, glomerular filtration rate; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide; hs‐TnT, high‐sensitivity troponin T; HDL‐C, high‐density lipoprotein–cholesterol; LDL‐C, low‐density lipoprotein–cholesterol.
P < .05; comparison between before and after treatment in all subject.
P < .05; comparison between before and after treatment in each group.
P < .05; comparison between dipeptidyl peptidase‐4 inhibitor and sodium glucose co‐transporter‐2 inhibitor groups.